Literature DB >> 19442778

A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents.

Helen Paterson1, Janelle Ashton, Mira Harrison-Woolrych.   

Abstract

BACKGROUND: While the use of the levonorgestrel intrauterine device (LNG-IUD) is well established in the adult population, there have been no research studies specifically on the use of the LNG-IUD in adolescents. STUDY
DESIGN: A nationwide cohort study of 179 adolescents in New Zealand using the LNG-IUD, by means of a follow-up questionnaire to their practitioner, was conducted to determine the indications for insertion of the LNG-IUD and to establish patterns of use, including duration of use and reasons for removal.
RESULTS: The study, with a 94% response rate, demonstrated that the most common indication for use was menorrhagia (17%); 29% of adolescents had an "off-label" primary indication. There was a 1-year continuation rate of 85%. The cumulative incidence of expulsion was 8%.
CONCLUSION: The results of this study should be reassuring for practitioners and adolescents considering use of the LNG-IUD. However, further research is required into the safety and efficacy of the LNG-IUD in adolescents especially in the management of off-label indications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19442778     DOI: 10.1016/j.contraception.2008.12.001

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  10 in total

1.  Use of the Copper T380A intrauterine device by adolescent mothers: continuation and method failure.

Authors:  Loral Patchen; Erica K Berggren
Journal:  J Pediatr Adolesc Gynecol       Date:  2010-09-24       Impact factor: 1.814

2.  Levonorgestrel intrauterine system as a treatment option for severe menorrhagia in adolescent with type III von Willebrand disease.

Authors:  Carla Donato Silva; Fernanda Geraldes; Isabel Santos Silva
Journal:  BMJ Case Rep       Date:  2013-04-30

3.  Precision intrauterine contraception may significantly increase continuation of use: a review of long-term clinical experience with frameless copper-releasing intrauterine contraception devices.

Authors:  Dirk Wildemeersch; Ansgar Pett; Sohela Jandi; Thomas Hasskamp; Patrick Rowe; Marc Vrijens
Journal:  Int J Womens Health       Date:  2013-04-30

4.  The wandering Mirena: laparoscopic retrieval.

Authors:  Mark Erian; Glenda McLaren; David Baartz
Journal:  JSLS       Date:  2011 Jan-Mar       Impact factor: 2.172

5.  Use of frameless intrauterine devices and systems in young nulliparous and adolescent women: results of a multicenter study.

Authors:  Dirk Wildemeersch; Sohela Jandi; Ansgar Pett; Kilian Nolte; Thomas Hasskamp; Marc Vrijens
Journal:  Int J Womens Health       Date:  2014-08-06

6.  New intrauterine technologies for contraception and treatment in -nulliparous/adolescent and parous women.

Authors:  D Wildemeersch
Journal:  Facts Views Vis Obgyn       Date:  2009

Review 7.  Femilis(®) 60 Levonorgestrel-Releasing Intrauterine System-A Review of 10 Years of Clinical Experience.

Authors:  Dirk Wildemeersch; Amaury Andrade; Norman Goldstuck
Journal:  Clin Med Insights Reprod Health       Date:  2016-08-09

8.  Expulsion and continuation rates after postabortion insertion of framed IUDs versus frameless IUDs - review of the literature.

Authors:  Dirk Wildemeersch; Norman D Goldstuck
Journal:  Open Access J Contracept       Date:  2015-07-09

9.  Intrauterine device quo vadis? Why intrauterine device use should be revisited particularly in nulliparous women?

Authors:  Dirk Wildemeersch; Norman Goldstuck; Thomas Hasskamp; Sohela Jandi; Ansgar Pett
Journal:  Open Access J Contracept       Date:  2015-01-16

10.  The levonorgestrel intrauterine device in Australia: analysis of prescribing data 2008-2012.

Authors:  Amie L Bingham; Cameryn C Garrett; Christine Bayly; Anne M Kavanagh; Louise A Keogh; Rebecca J Bentley; Jane S Hocking
Journal:  BMC Womens Health       Date:  2018-11-27       Impact factor: 2.809

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.